# Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

> **NCT00597909** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 1 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** sodium phenylacetate and sodium benzoate injection 10% / 10%
- **DRUG:** sodium phenylacetate and sodium benzoate injection 10% / 10%
- **DRUG:** placebo solution (10% dextrose)

## Key facts

- **NCT ID:** NCT00597909
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was terminated due to lack of enrollment and business decisions.
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00597909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00597909, "Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00597909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*